Raymond James Financial
DFTX icon

Raymond James Financial’s Definium Therapeutics DFTX Stock Holding History

Raymond James Financial’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.6M Buy
42,039
+19,638
+88% +$828K ﹤0.01% 3678
2026
Q2 		$1.05M Sell
22,401
-1,312
-6% -$32.4K ﹤0.01% 3960
2026
Q1 		$448K Buy
23,713
+2,592
+12% +$44K ﹤0.01% 4421
2025
Q4 		$283K Buy
21,121
+3,329
+19% +$41.2K ﹤0.01% 4612
2025
Q3 		$210K Buy
17,792
+763
+4% +$7.12K ﹤0.01% 4602
2025
Q2 		$111K Sell
17,029
-1,450
-8% -$9.5K ﹤0.01% 4826
2025
Q1 		$108K Buy
18,479
+2,475
+15% +$17.7K ﹤0.01% 4536
2024
Q4 		$111K Buy
+16,004
New +$110K ﹤0.01% 4512

Other funds holding DFTX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $33.4B AUM 56.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Raymond James Financial's DFTX Position: Q3 2026 in Review

Raymond James Financial increased its Definium Therapeutics (DFTX) stake by 88% in Q3 2026, buying an estimated $828K and bringing the position to 42,039 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3678.

Raymond James Financial first reported a position in DFTX in Q4 2024 and has held it in 8 quarters since. 253 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Raymond James Financial held 42,039 shares of Definium Therapeutics worth $1.6M as of Q3 2026.
  • Raymond James Financial bought 19,638 Definium Therapeutics shares in Q3 2026, an estimated $828K.
  • Definium Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #3678 holding.
  • Raymond James Financial first reported a position in Definium Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • 253 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.